BDP1 and ovarian serous carcinoma: These analyses demonstrate that BDP1 alterations in ovarian cancer are mostly deep deletions (3.95%), correlate with decreased expression in serous ovarian carcinoma (Figure 1A‐B) and that BDP1 alterations negatively impacted disease‐free progression in patients with ovarian cancer (p = 0.0271, q = 0.0542) (Figure 1C).